Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imagabalin
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Imagabalin is a small molecule investigational drug that was developed by Pfizer as a ligand for the α2δ subunit of voltage-dependent calcium channels, with some selectivity for the α2δ1 subunit over α2δ2. It belongs to the gabapentinoid class and was hypothesized to have anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. Imagabalin reached phase III clinical trials for generalized anxiety disorder (GAD), but development was discontinued due to insufficient efficacy compared to existing treatments. Its safety profile was similar to other gabapentinoids[3][6][7].
- Other names
- imagabalin hydrochloride
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on imagabalin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imagabalin.